Discrete trajectories of resolving and persistent pain in people with rheumatoid arthritis despite undergoing treatment for inflammation: Results from three UK cohorts

Daniel F McWilliams, Olivia Dawson, Adam Young, Patrick DW Kiely, Eamonn Ferguson, David A Walsh

PII: S1526-5900(18)30478-4
DOI: https://doi.org/10.1016/j.jpain.2019.01.001
Reference: YJPAI 3678

To appear in: Journal of Pain

Received date: 6 September 2018
Revised date: 6 December 2018
Accepted date: 2 January 2019

Please cite this article as: Daniel F McWilliams, Olivia Dawson, Adam Young, Patrick DW Kiely, Eamonn Ferguson, David A Walsh, Discrete trajectories of resolving and persistent pain in people with rheumatoid arthritis despite undergoing treatment for inflammation: Results from three UK cohorts, Journal of Pain (2019), doi: https://doi.org/10.1016/j.jpain.2019.01.001

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
3-5 highlights points with an 85 character limit including spaces

- Pain progression is heterogeneous in people with rheumatoid arthritis
- Persistent pain is predicted by high disability
- Even when inflammation resolves, the commonest trajectory is Persistent Pain
- Additional pain management might help people with rheumatoid arthritis
Discrete trajectories of resolving and persistent pain in people with rheumatoid arthritis despite undergoing treatment for inflammation: Results from three UK cohorts.

Daniel F McWilliams¹,², Olivia Dawson¹,², Adam Young³, Patrick DW Kiely⁴, Eamonn Ferguson*¹,⁵, David A Walsh*¹,²,⁶

* - both authors contributed equally to this study.

1 Arthritis Research UK Pain Centre and NIHR Nottingham Biomedical Research Centre, University of Nottingham, UK.

2 Division of ROD, University of Nottingham, UK.

3 Centre for Health Services & Clinical Research (CHSCR) & Postgraduate Medicine, University Herts, Hatfield, UK.

4 Department Rheumatology, St Georges University Hospitals NHS Foundation Trust, London, UK.

5 School of Psychology, University of Nottingham, UK.

6 Department of Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton in Ashfield, UK, and Nottingham University Hospitals NHS Trust.

Figures: 2
Tables: 4
Supplement figures: 2

Keywords: rheumatoid arthritis, pain, inflammation, trajectory, cohort

Abbreviations: SF36-Short Form-36 questionnaire, RA – rheumatoid arthritis, HAQ – health assessment questionnaire, BSRBR – British Society for Rheumatology Biologics Register, ERAN-Early Rheumatoid Arthritis Network, BMI-body mass index, RF-rheumatoid factor, ESR-erythrocyte sedimentation rate, TJC-tender joint count, SJC-swollen joint count, VAS-visual analogue scale, DAS28-28 joint disease activity score, GMM – Growth Mixture Modelling, AIC – Akaike Information Criteria, BIC – Bayesian Information Criteria, ssBIC-sample-size adjusted BIC LMR-LRT -Lo-Mendell-Rubin likelihood ratio test, BLRT- bootstrap likelihood ratio test. VAS-GH-visual analogue scale-general health, DMARD-disease-modifying anti-rheumatic drug, SD-standard deviation, CI-confidence interval, ACR-American College of Rheumatology.
Author disclosures:

DAW and DFM declare grant support from Pfizer. This study was funded by an iCRP grant from Pfizer UK (ref: WI190792). DAW declares consultancy work for Pfizer and GlaxoSmithKline. Other authors have no disclosures.

Email addresses: dan.mcwilliams@nottingham.ac.uk, mzyod1@exmail.nottingham.ac.uk, Patrick.Kiely@stgeorges.nhs.uk, adam.young@nhs.net, Eamonn.ferguson@nottingham.ac.uk, david.walsh@nottingham.ac.uk
Abstract

Rheumatoid arthritis (RA) is an example of human chronic inflammatory pain. Modern treatments suppress inflammation, yet pain remains a major problem for many people with RA. We hypothesised that discrete RA subgroups might display favourable or unfavourable pain trajectories when receiving treatment, and that baseline characteristics will predict trajectory allocation.

Growth Mixture Modelling was used to identify discrete trajectories of SF36-Bodily Pain scores during 3 years in 3 RA cohorts (Early RA Network (ERAN); n=683, British Society for Rheumatology Biologics Register Biologics (n=7090) and Non-Biologics (n=1720) cohorts. Logistic regression compared baseline predictor variables between trajectories. The role of inflammation was examined in a subgroup analysis of people with normal levels of inflammatory markers after 3 years.

Mean SF36-Bodily Pain scores in each cohort improved but remained throughout 3y follow up >1 SD worse than the UK general population average. Discrete Persistent Pain (59% to 79% of cohort participants) and Resolving Pain (19% to 27%) trajectories were identified in each cohort. In ERAN, a third trajectory displaying persistently Low Pain (23%) was also identified. In people with normal levels of inflammatory markers after 3 years, 65% of them were found to follow a Persistent Pain trajectory. When trajectories were compared, greater disability (aORs 2.3-2.5 per unit baseline Health Assessment Questionnaire score) and smoking history (aORs 1.6-1.8) were risk factors for Persistent Pain trajectories in each cohort.

In conclusion, distinct trajectories indicate patient subgroups with very different pain prognosis during RA treatment. Inflammation does not fully explain the pain trajectories, and non-inflammatory factors as well as acute phase response predict which trajectory an individual will follow. Targeted treatments additional to those which suppress inflammation might reduce the long term burden of arthritis pain.
**Perspective**

Immunosuppression reduces inflammation in RA, but pain outcomes are less favourable. Discrete Persistent and Resolving Pain trajectories were identified following treatment, both in early and established RA. Smoking and higher disability at baseline predicted persistent pain. Identifying patient subgroups with poor pain prognosis could enable adjunctive treatment to improve outcome.
Introduction

Arthritis is a common cause of chronic musculoskeletal pain and disability; especially across ageing populations. Arthritis has traditionally been classified as either inflammatory (e.g. rheumatoid arthritis; RA) or non-inflammatory (e.g. osteoarthritis; OA, the commonest reason for joint replacement surgery). RA is a systemic, autoimmune condition with a predilection for synovial joints of the hands and feet. Synovitis (inflammation of the joint lining) contributes to pain, and also leads to joint damage. Important contributions of inflammation to OA pain are now well recognised 33, although RA remains the prototypical form of inflammatory arthritis. Pain is cited by patients as the most important symptom of RA. Early intensive immunosuppressive treatment in people with RA aims to prevent long term pain and disability 34. Disease modifying anti-rheumatic drugs (DMARDs) and glucocorticoids can reduce inflammation for many people with RA, and can also reduce pain. Those who do not respond adequately to conventional synthetic (cs)DMARDs might yet benefit from biologic (b)DMARDs such as tumour necrosis factor (TNF)α inhibitors.

While clinical experience confirms that many people benefit greatly from current treatments 34, chronic pain remains the most difficult problem for many people with RA 30. At a population level, average pain incompletely improves after DMARDs are commenced or changed 1,30, and mean pain scores for RA populations remain worse than UK population mean values even 12 months after baseline 30,31. Pain can remain problematic even when inflammatory disease is in remission 26, suggesting important pain mechanisms additional to ongoing inflammation. Central sensitisation might contribute to RA pain 22,51, whereas joint damage might now be less important following introduction of effective DMARDs 7. Subgroups of people with RA have been identified for whom non-inflammatory mechanisms might contribute to ongoing pain and high clinical scores for disease activity 28,51, and interest exists about whether they represent distinct phenotypes of RA.

Reporting of mean effects might conceal subgroups of people with quite different outcomes, as people with RA display heterogeneous prognosis and response to treatment. One year after commencing bDMARDs, more than 50% of people with RA reported pain at problematic levels 30. Other studies have reported heterogeneity between individuals in the progression of other aspects of RA, such as trajectories of disease activity, functional limitations, fatigue and mental distress 11,12,36,37,45. Previous study of disease trajectories has focused on single study groups. However, pain trajectories might either be generic or specific to particular patient or treatment groups 20. Comparing different patient groups allows us to identify generic factors that might be amenable to interventions aiming to improve patient outcomes.
We hypothesised that patient subgroups exist that display different pain trajectories, and that these trajectories are shared across people with early or established RA receiving csDMARDs or bDMARDs. The aim of this study was to identify discrete pain trajectories in people with RA and then to examine factors that might explain which trajectory individuals will follow. We analysed data from 3 well-described hospital-based cohorts, which varied in disease duration and treatment regimens. The Early RA Network (ERAN) is an inception cohort which recruited people at physician diagnosis of RA. The 2 British Society for Rheumatology Biologics Registry (BSRBR) cohorts studied here recruited participants with established and active RA either on commencing TNFα inhibitors (BSRBR Biologics cohort) or not initiating bDMARD treatment (BSRBR Non-Biologics cohort). We explore whether subgroups with different disease progression vary as a function of treatment (BSRBR Biologics cohort vs BSRBR Non-Biologics cohort) or disease stage (BSRBR cohorts vs ERAN). In order to explore whether factors other than inflammation might determine pain progression we also examined pain trajectories in the sub-group of participants with normalisation of acute phase response and swollen joint count.

Methods

Patients and Recruitment

The Early Rheumatoid Arthritis Network (ERAN) inception cohort collected data from outpatient clinics in the UK and Eire \(^{16,24}\). Patients were recruited when they were diagnosed with RA by a consultant rheumatologist. The British Society for Rheumatology Biologic Register (BSRBR) cohorts collected data from outpatient clinics in the UK \(^{46}\). The BSRBR-Biologics cohort recruited people who were starting biologics as part of their routine care, having failed to respond adequately to other DMARDs. The BSRBR-Non-Biologics cohort recruited people with RA who were using non-biologic DMARDs. Both BSRBR cohorts were observational studies of people predominantly with active RA \(^{18}\). Data used for this study were provided for baseline, and up to 3 years follow up, between 2002 and 2013. The data from BSRBR were collected, stored and managed at the University of Manchester, UK.

UK National Health Service ethical approvals were in place for ERAN (Trent Research Ethics Committee reference 01/4/047) and the 2 BSRBR cohorts (North West Multicentre Research Ethics Committee reference 00/8/53). All participants gave signed informed consent in line with the Declaration of Helsinki.
Data collection for all cohorts was from multiple centres and included physical examinations, interviews and reference to medical notes. Data collected that were common to all 3 cohorts included age, sex, smoking, 28-joint disease activity score (DAS28 \(^{48}\), which is a composite score derived from erythrocyte sedimentation rate (ESR) in mm per hour, 100mm visual analogue scale-general health (VAS-GH), tender joint count for 28 joints (TJC) and swollen joint count for the same 28 joints (SJC), body mass index (BMI), serology (seropositive \(^{25}\) was defined as testing positive for either Rheumatoid Factor (RF) or citrullinated proteins according to each study centre’s normal ranges), 1987 American College of Rheumatology (ACR) diagnostic criteria (5/7 clinical features) \(^{3}\), health assessment questionnaire (HAQ) for disability \(^{6}\), and Short Form-36 (SF36) \(^{50}\). SF-36 subscale data were used to estimate pain (Bodily Pain), disability (Physical Function), fatigue (Vitality) and psychological health (Mental Health). SF-36-Bodily Pain assesses the severity of pain and its impact upon daily activities \(^{50}\). Pain data from people providing baseline and at least 50% of follow up data points were included in analyses. SF-36 data were norm transformed to the expected UK population estimates following standard methodology \(^{21}, 50\). Briefly, this z-transformation normalises the SF36 data from this study to the measured mean of 50 and standard deviation (sd) of 10 from the UK population, taking age and gender structure into account. Therefore a normed SF36 score of 50 is the expected average for the UK general population. In the BSRBR-Non-Biologics cohort, the DAS28 components were only available at baseline. Co-morbidities were classified as present or absent. Further to the data collected, rearrangements were derived of the DAS28 formula, designed to act as surrogate indices of central sensitisation and/or non-inflammatory pain; DAS28-P (the proportion of DAS28 derived from patient-reported variables, TJC and VAS-GH) \(^{22}, 31\) and Tender-Swollen Difference (TSD; TJC minus SJC) \(^{40}\).

**Statistical Analysis**

**Trajectories of pain**

The norm-transformed SF36-Bodily Pain data were examined for trajectories of progression from baseline to 3 years. Each cohort was examined separately using the descriptive technique of linear growth mixture modelling (GMM) to allow the separation of latent subgroups of people based upon similarities between their pain trajectories. GMM is related to structural equation modelling, and will statistically select groups of people with similar trajectories. We performed GMM to produce models with increasing numbers of trajectories, starting with 1 trajectory, and then examined model selection criteria to inform the optimal model choice and the addition of another trajectory (see below). Additional trajectories were selected until the criteria suggested that no more should be selected, and there was no predetermined numbers of trajectories for each cohort.

**Model selection criteria**
The Akaike Information Criteria (AIC), Bayesian Information Criteria (BIC), sample-size adjusted BIC (ssBIC) were used to estimate the amount of information lost within models, and higher values indicated worse performance. Entropy described the overall probability of the cases being assigned to the correct trajectory. The Lo-Mendell-Rubin likelihood ratio test (LMR-LRT) and bootstrap likelihood ratio test (BLRT) were significance tests comparing the fit for the model with k trajectories to the model with k-1 trajectories (statistical significance indicated an improved fit compared to the k-1 model). Trajectory membership numbers consisting of <5% of the sample were automatically rejected. Trajectories were named to describe their pain prognosis. The findings were confirmed by repeating the analyses of optimal trajectories while accounting for the distribution and frequency of missing data by using pattern mixture analysis. This adjusted for missing data by examining pain at timepoint t and its association with missing pain data at timepoint t+1.

Analysis of inflammation and pain

Additional analysis was performed to assess the pain trajectories in participants with very low inflammation at follow up. These people were selected if they had both a 0/28 swollen joint count and ESR reading of ≤22 (men) or ≤29 (women) at the 3 year study visit. The GMM and pattern mixture models for pain trajectories were also performed in this subgroup of the BSRBR-Biologics cohort.

Comparisons across trajectories

Baseline differences between people allocated to each trajectory were examined using ANOVAs with a Bonferroni correction and Pearson Chi-square. Multinomial or binary logistic regression was performed to find variables that predicted membership of pain trajectories. The conditional probabilities of trajectory membership were used to derive probability weights, which were used to confirm that the logistic regression analyses were not unduly influenced by cases where trajectory was less certain.

Progression of important clinical measures

The mean longitudinal progression of DAS28 (the disease activity index and its composite variables) and HAQ-disability were plotted for the membership of each pain trajectory.

Software

GMM, pattern mixture models were performed using Mplus (Muthen and Muthen, Los Angeles, USA) and all other statistics and data management was performed using SPSS v22 (IBM, Chicago, USA).
Results

Study demographics

Baseline demographics were similar between the 3 cohorts, except that ERAN participants had shorter symptom duration and were more likely to smoke, and the BSRBR-Biologics participants had overall more severe disease activity and disability (Table 1). Mean SF36-Bodily Pain scores improved between baseline and first follow up (p<0.001 for each cohort), but remained throughout the 3 year follow up >1 SD (10 points) worse than values normalised to the expected UK population average (Figure 1a).

Description of trajectories

The trajectory modelling process is summarised in Table 2. For ERAN, a 3 trajectory model was optimal, by reference to the AIC, BIC, ssBIC, LMR-LRT and BLRT. In the BSRBR-Biologics and Non-Biologics cohorts, 2 trajectory models were selected. Three trajectory models were rejected for the BSRBR cohorts due to the small membership numbers (<4% of participants) in one trajectory within each 3 trajectory model (Table 2). The mean SF36-Bodily Pain scores over time for each trajectory are shown in Figure 1b-d. The GMMs provided probabilities for each person of being allocated to the correct trajectory. These are the entropy scores (Table 2).

In ERAN, the most populous of the 3 trajectories (59% of participants) showed a consistently high mean pain level across the 3 years (Persistent Pain trajectory). A second trajectory (23%) showed a consistently low mean pain level across the 3 years, approximating closely to the expected UK population average for Bodily Pain scores of 50 (Low Pain trajectory). The third trajectory (19%) showed an initially high mean pain level at baseline that improved approaching the expected UK population average across the three years (Resolving Pain trajectory; Figure 1b).

In the BSRBR-Biologics cohort, each of the 2 trajectories showed improvement from baseline to 6 months (Figure 1c). In the most populous trajectory (79% of participants), mean Bodily Pain scores remained worse, by a clinically important extent, than expected UK population means during the 3 year follow up (Persistent Pain trajectory). In the second trajectory (21%), Bodily Pain scores improved to approach the expected UK population mean (Resolving Pain trajectory).
In the BSRBR-Non-Biologics cohort, 2 trajectories were again identified (Figure 1d). The most populous trajectory (73% of participants) showed persistent high mean pain levels (Persistent Pain trajectory), whereas in the other trajectory (27%) Bodily Pain scores improved to approach the expected UK population mean (Resolving Pain trajectory).

**Pain trajectories in people attaining very low inflammation**

Analysis was performed in the subgroup of people from the BSRBR-Biologics cohort with very low inflammation at the 3 year study visit (SJC = 0/28 and ESR ≤22 in men and ≤29 in women; n=1199, with n=570 giving complete SF36-Bodily Pain across all time points). This was performed to investigate whether those people with inflammation that returned to normal levels formed a single (Resolving Pain) trajectory. As in the host cohorts, in this subgroup the 2 trajectories of Persistent Pain (n=777, 65%) and Resolving Pain (n=422, 35%) were also found (see Figure 2).

**Baseline characteristics compared between people in discrete trajectories**

Baseline demographics, clinical measures and self-reported questionnaire scores were compared between trajectories. In univariate analyses (Table 3), baseline variables that were heterogeneous between different trajectories within each of the 3 cohorts were BMI, DAS28, Tender Joint Count, Tender-Swollen Difference, DAS28-P, HAQ disability scores, comorbidities, SF36-Physical Function, -Vitality and -Mental Health scores, and smoking status. In ERAN, additional pairwise analyses were performed examining the differences at baseline between the Persistent Pain and the Resolving Pain trajectories. Mean baseline DAS28 was similar between these 2 trajectories, but the Persistent Pain trajectory had significantly higher baseline BMI (p=0.019), Tender-Swollen Difference (p<0.001), DAS28-P (p=0.001), HAQ disability scores (p=0.008), more comorbidities (p=0.012), less Vitality (p=0.023), and fewer people that had never smoked (p=0.042) (Table 3). Baseline SF36-Bodily Pain scores were similar between Persistent and Resolving Pain trajectories in ERAN.

Variables associated with heterogeneity were examined as independent predictors of allocation to each trajectory, and adjusted odds ratios were generated using multinomial and binary logistic regression (Table 4). The baseline variables that showed significant independent associations with Persistent rather than Resolving Pain trajectories in all cohorts were higher HAQ disability score and smoking (either current or ex-smokers; Table 4). In ERAN, baseline variables showing significant and independent associations with Low rather than Persistent Pain trajectory were lower Bodily Pain, lower HAQ disability and never smoking (Table 4). The significant findings from the logistic regression analyses in each of the 3 cohorts were retained when probability weightings were used to adjust for the likelihood of trajectory membership.
Secondary analyses of all cohorts (and all eligible cases) replaced DAS28 with either its 4 components or derived variables in order to explore possibly divergent associations of pain trajectory with baseline inflammatory or non-inflammatory factors contributing to disease activity scores. When all 4 DAS28 component variables were included in the model lower ESR was associated with the Resolving Pain trajectories in ERAN (aOR; 0.99, 95% CI 0.98 to 1.00) and in the BSRBR-Biologics (aOR: 1.00, 95% CI 0.99 to 1.00) cohorts, but not significantly so in the BSRBR-Non-Biologics cohort. Associations between other baseline DAS28 components or derived variables and pain trajectory did not replicate between cohorts.

**Progression of other important outcomes**

The longitudinal progression of other key clinical outcomes (DAS28 and HAQ disability) generally followed the progression observed in Bodily Pain scores in each pain trajectory in each cohort (Supplement Figure 1). People allocated to Persistent Pain trajectories displayed persistently high or increasing HAQ disability, and mean DAS28 scores that might initially improve, but remained higher than other trajectories in all cohorts. HAQ disability and DAS28 scores in the Resolving Pain trajectories converged with the low levels of disability and disease activity observed in ERAN throughout the Low Pain trajectory. Longitudinal progression of DAS28 components also followed pain progression in BSRBR cohort Pain trajectories (Supplement Figure 2). However, in ERAN, although VAS and Tender Joint Count remained increased in the Persistent Pain group, ESR and Swollen Joint Counts decreased by 3 years to levels that were similar in all 3 pain trajectory groups (Supplement Figure 2).

**Discussion**

RA is an example of chronic inflammatory pain. Mean Bodily Pain scores of people with RA improved during treatment of inflammation, but remained worse than the expected UK general population average throughout 3 years follow up. However, this average conceals discrete subgroups of patients who experience very different favourable or unfavourable pain progressions. Baseline inflammation predicted good poor pain trajectories, but suppression of inflammation did not invariably lead to a good pain prognosis. Non-inflammatory factors such as smoking status and disability predicted allocated to the Persistent Pain trajectory. Targeted treatments additional to those which suppress inflammation might improve prognosis in those otherwise destined to suffer chronic pain.

**Pain prognosis in RA**
Many people with RA do very well on modern DMARD therapies by many measures of success. However, we show that a substantial majority (65%) of people achieving low inflammatory disease suffers from persistent pain. We previously showed that people presenting with active RA continued to report worse pain scores than the population average one year later 30, 31, and now show that pain persists over a 3 year follow up. Improvements in mean Bodily Pain scores following the introduction of TNF-alpha blocking agents appear less than might be expected from improvements in inflammatory disease activity, as measured by DAS28. Seventeen percent of people might report DAS28 remission 12 months after bDMARD initiation 19, but we show that improvements occur in DAS28 during follow up even people with persistent pain.

Discrete pain trajectories in RA

We found that people with clinically-determined active RA can be stratified into discrete groups with good or poor pain prognosis. Although pain scores in one group decreased to the UK general population mean, a much larger group (up to 79% of cohort participants) continued to report persistent and substantial pain. The Persistent Pain trajectory was observed even in those whose inflammatory disease responded well to treatment. Thus, for this subgroup pain remains a consistent clinical problem despite effective treatment of inflammation.

Persisting and Resolving Pain trajectories were replicated across different cohorts, including patients with differing disease duration (early or established RA) or on different treatments (cDMARD or bDMARD). Discrete persistent and improving pain trajectories might also be observed in juvenile idiopathic arthritis 43, but have not previously been elucidated in adult RA. Discrete persistent and improving trajectories have been found in RA for disease activity scores 5, 10, psychological distress 37 or disability 36. Persistently high psychological distress or high disability trajectories also displayed higher baseline pain scores, and less improvement in pain over 3 year follow up 36, 37. However, our findings on RA pain differ in some important ways from these other patient outcomes. The Persistent Pain trajectories in our cohorts were more populous (59%-79%) than unfavourable trajectories for other outcomes of disease activity (2.6 to 10.7%), psychological distress (12%) 37 or disability (15 to 20%) 36. We showed that many people with good suppression of disease activity have persistent pain, and these data indicate that many people with favourable trajectories of distress or disability also continue to experience pain.

Predictors of pain trajectory allocation and therapeutic implications
Persistent Pain trajectory allocation was associated with lower inflammatory (ESR) and worse non-inflammatory (disability, smoking) characteristics at baseline. Our observations that seropositivity was not significantly associated with pain trajectory, and that lower ESR at baseline predicted Persistent Pain trajectory allocation, contrasts with predictors of poor inflammatory disease prognosis. This might indicate a lesser contribution of DMARD-modifiable inflammation to persistent pain in our patient groups. Treatments that suppress inflammatory disease, both csDMARDs and bDMARDs as used by patients in these cohorts, might be most effective at reducing pain in those with objective evidence of inflammation, for example raised ESR. Persistent inflammation might be expected to lead to persistent pain, but our findings show that Persistent Pain trajectories can be identified in people with little evidence of persistent inflammation.

We found that greater disability and smoking status at baseline indicated patients destined to follow a Persistent Pain trajectory across the 3 cohorts. Disability and smoking predicted pain trajectory allocation independent on inflammation measures, and baseline disability and smoking similarly predicted pain prognosis in conditions not usually associated with joint inflammation.

Identifying people destined to have persistent pain might help target additional pain management strategies that might be employed in parallel to DMARD treatment. Such evidence-based treatments might include cognitive behavioural therapies, although integration of medical and psychological approaches can prove challenging.

Further research might also explore whether predictive factors (disability and smoking status) identified in the current study indicate non-inflammatory pain mechanisms that are amenable to specific interventions. Increasing physical activity can reduce musculoskeletal pain. Supervised exercise in RA can reduce both pain and disability, suggesting a direct link between maintaining activity and improved pain prognosis. Smoking might alter pain processing, inflammatory disease activity, or response to treatment. Possible effects of smoking cessation interventions on RA pain deserve further study.

Beyond baseline variables measured in the current study, other factors might be important in driving persistent pain in RA, including alterations in pain processing such as central sensitisation. Central sensitisation can also inflate DAS28 and non-inflammatory mechanisms might explain our finding that DAS28 itself predicted pain prognosis during DMARD therapy less well than did the objective measure of inflammation, ESR. A high proportion of DAS28 derived from patient reported components (high DAS28-P) at baseline, or a higher Tender-Swollen Joint Count difference in those allocated to the Persistent Pain trajectory might suggest greater central sensitisation. Tender-Swollen Difference
predicted pain trajectory in people with early RA in the current study, but these derived measures did not significantly predict pain trajectory in established disease. Similarly, others have not found derived measures to predict other outcomes in established RA. Further research would be needed to determine whether improved measures of central sensitisation, for example using quantitative sensory testing, might predict pain prognosis better than DAS28 derived measures.

**Study limitations**

Our study is subject to a number of limitations. Each cohort was analysed separately and in parallel, and the baseline variables were not matched between cohorts. This limits comparisons between cohorts, but our consistent findings between cohorts suggest generalisability. Scales focussing on other aspects of pain, or with different sensitivities, might have produced different results to the SF36-Bodily Pain subscale. Different patient experiences after baseline assessment might alter psychological processes that moderate their interpretation and experience of pain, in addition to any effects of inflammatory disease. Effects of psychosocial risk factors on the different pain trajectories in people with RA deserve further attention in order to identify modifiable risks that might be targets for specific intervention. It is possible that different pain trajectories would be detected in other treatment contexts, such as clinical trials or in people already undergoing stable treatment. Furthermore we would be optimistic that different treatment regimens might increase patient allocation to Resolving Pain trajectories, which only accounted for approximately one quarter of our study populations. The Low Pain trajectory identified in ERAN, characterised by low pain at baseline, was not replicated in the BSRBR cohorts. This is likely due to eligibility criteria for inclusion in BSRBR requiring high disease activity and recruitment taking place at a time when new medications were being prescribed. People commencing biologics in the UK usually have DAS28 > 5.1 and are highly symptomatic. Conversely, ERAN participants were not recruited based upon any thresholds of disease activity measurements (beyond those required to achieve diagnosis). Another reason for this different trajectory in ERAN might be that pain in early RA might be more amenable to successful DMARD treatment. Current practice is guided by evidence that intensive early treatment of RA improves long term outcomes.

**Conclusions**

Persistent pain remains a major clinical challenge in RA, despite modern treatment of inflammation. Our data indicate that discrete groups of people with RA are destined to experience persistent or resolving pain. Persistent Pain trajectories cannot be adequately explained by persistent inflammatory disease activity, and this might reflect life style factors
or central sensitization, both of which might be amenable to intervention. Inflammation might also contribute to pain in other forms of arthritis, including OA. However, if suppressing inflammation alone does not prevent persistent pain in RA, then anti-inflammatory approaches are unlikely to provide a complete solution for chronic pain in these other conditions. Further work might investigate the aetiology of pain in joints with no evidence of inflammation. RA provides an important human model of pain in which inflammation and non-inflammatory factors interact. Identifying subgroups destined to display different pain trajectories should help improve clinical trial design, treatment allocation and, ultimately, pain outcomes for people with RA.
Declarations

Ethics approval and consent to participate:

UK National Health Service ethical approvals were in place for ERAN (Trent Research Ethics Committee reference 01/4/047) and the 2 BSRBR cohorts (North West Multicentre Research Ethics Committee reference 00/8/53). All participants gave signed informed consent in line with the Declaration of Helsinki.

Consent for publication:

No further consent for publication of materials were required.

Availability of data and material:

Data from BSRBR are available from Drs Alan Roach and Chris Hiley (British Society for Rheumatology, London). Data were prepared and provided by Prof Kimme Hyrich, Drs Kath Watson and Katie McGruther (University of Manchester).

The ERAN study database is currently held at the University Of Nottingham (please direct requests for data to DAW).

Competing interests:

DFM and DAW declare research support from Pfizer (WI190792). DAW declares consultancy work for Pfizer and Glaxo Smith Kline.

Funding:

This study was funded by an iCRP grant from Pfizer UK (ref: WI190792).

Author contributions:

Study design: DFM, DAW, EF, OD, PDK, AY

Data collection: DAW, PDK, AY

Analysis: OD, DFM, EF, DAW

Critical appraisal of analysis: DFM, DAW, EF, OD, PDK, AY

Writing and editing manuscript: DFM, DAW, EF, OD, PDK, AY
Approval of final version of manuscript: DFM, DAW, EF, OD, PDK, AY

Acknowledgements:

We would like to acknowledge the contribution of the helpful discussions we had with Dr Sam Norton (King's College London).
References

1. Altawil R, Saevarsdottir S, Wedren S, Alfredsson L, Klareskog L, Lampa J. Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate. *Arthritis care & research.* 68:1061-1068, 2016

2. Amin S, Niu J, Guermazi A, Grigoryan M, Hunter DJ, Clancy M, LaValley MP, Genant HK, Felson DT. Cigarette smoking and the risk for cartilage loss and knee pain in men with knee osteoarthritis. *Annals of the rheumatic diseases.* 66:18-22, 2007

3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger Jr TS, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis and rheumatism.* 31:315-324, 1988

4. Baillet A, Zeboulon N, Gossec L, Combescure C, Bodin LA, Juvin R, Dougados M, Gaudin P. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. *Arthritis care & research.* 62:984-992, 2010

5. Barnabe C, Sun Y, Boire G, Hitchon CA, Harauoi B, Thorne JC, Tin D, van der Heijde D, Curtis JR, Jamal S, Pope JE, Keystone EC, Bartlett S, Bykerk VP, Investigators C. Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). *PLoS One.* 10:e0135327, 2015

6. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. *The Journal of rheumatology.* 30:167-178, 2003

7. Carpenter L, Norton S, Nikiphorou E, Jayakumar K, McWilliams DF, Rennie KL, Dixey J, Kiely P, Walsh DA, Young A, Early Rheumatoid Arthritis S, the Early Rheumatoid Arthritis N. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. *Arthritis care & research.* 69:1809-1817, 2017

8. Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI. Smoking and rheumatoid arthritis. *Int J Mol Sci.* 15:22279-22295, 2014

9. Christensen AW, Ribibjerg-Madsen S, Christensen R, Dreyer L, Boesen M, Ellegaard K, Bliddal H, Danneskiold-Samsoe B, Amris K. Ultrasound Doppler but not temporal summation of pain predicts DAS28 response in rheumatoid arthritis: a prospective cohort study. *Rheumatology (Oxford).* 55:1091-1098, 2016
10. Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A. Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. *EBioMedicine*. 11:302-306, 2016

11. Demmelmaier I, Dufour AB, Nordgren B, Opava CH. Trajectories of Physical Activity Over Two Years in Persons With Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 68:1069-1077, 2016

12. Druc KL, Jones GT, Macfarlane GJ, Verstappen SM, Basu N. The Longitudinal Course of Fatigue in Rheumatoid Arthritis: Results from the Norfolk Arthritis Register. *J Rheumatol*. 42:2059-2065, 2015

13. Dunlop DD, Song J, Semanik PA, Sharma L, Chang RW. Physical activity levels and functional performance in the osteoarthritis initiative: a graded relationship. *Arthritis Rheum*. 63:127-136, 2011

14. Ferguson E. Personality is of central concern to understand health: towards a theoretical model for health psychology. *Health Psychol Rev*. 7:S32-S70, 2013

15. Ferguson E, Lievens F. Future directions in personality, occupational and medical selection: myths, misunderstandings, measurement, and suggestions. *Adv Health Sci Educ Theory Pract*. 22:387-399, 2017

16. Garwood W. The Early Rheumatoid Arthritis Network (ERAN). *Musculoskeletal care*. 2:240-244, 2004

17. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwerverman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendaal JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. *Arthritis and Rheumatism*. 58:S126-135, 2008

18. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum*. 54:1786-1794, 2006

19. Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. *Rheumatology (Oxford)*. 50:117-123, 2011

20. James RJE, Walsh DA, Ferguson E. General and disease-specific pain trajectories as predictors of social and political outcomes in arthritis and cancer. *BMC Med*. 16:51, 2018
21. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. *Journal of epidemiology and community health.* 53:46-50, 1999

22. Joharatnam N, McWilliams DF, Wilson D, Wheeler M, Pande I, Walsh DA. A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis. *Arthritis research & therapy.* 17:11, 2015

23. Jurgens MS, Overman CL, Jacobs JW, Geenen R, Cuppen BV, Marijnissen AC, Bijlsma JW, Welsing PM, Lafeber FP, van Laar JM, Utrecht Arthritis Cohort Study G. Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 67:923-928, 2015

24. Kiely P, Walsh D, Williams R, Young A, Early Rheumatoid Arthritis N. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN). *Rheumatology (Oxford, England).* 50:926-931, 2011

25. Lee AN, Beck CE, Hall M. Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review. *Clin Lab Sci.* 21:15-18, 2008

26. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME, Solomon DH. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. *Arthritis research & therapy.* 13:R83, 2011

27. Little RJ, Wang Y. Pattern-mixture models for multivariate incomplete data with covariates. *Biometrics.* 52:98-111, 1996

28. McWilliams DF, Ferguson E, Young A, Kiely PD, Walsh DA. Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data. *Arthritis research & therapy.* 18:295, 2016

29. McWilliams DF, Joharatnam N, Wilson D, Young A, Kiely P, Walsh DA. Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoid arthritis. *BMC Rheumatology.* 2:8, 2018

30. McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour necrosis factor-alpha-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. *BMC Musculoskelet Disord.* 17:337, 2016

31. McWilliams DF, Zhang W, Mansell JS, Kiely PD, Young A, Walsh DA. Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. *Arthritis Care Res (Hoboken).* 64:1505-1513, 2012
32. Muthen B, Asparouhov T, Hunter AM, Leuchter AF. Growth modeling with nonignorable dropout: alternative analyses of the STAR*D antidepressant trial. *Psychol Methods*. 16:17-33, 2011

33. Neogi T, Guermazi A, Roemer F, Nevitt MC, Scholz J, Arendt-Nielsen L, Woolf C, Niu J, Bradley LA, Quinn E, Law LF. Association of Joint Inflammation With Pain Sensitization in Knee Osteoarthritis: The Multicenter Osteoarthritis Study. *Arthritis & Rheumatology*. 68:654-661, 2016

34. NICE: Rheumatoid arthritis - the management of rheumatoid arthritis in adults, HMSO, London, 2009.

35. Norton S, Fu B, Scott DL, Deighton C, Symmons DP, Wailoo AJ, Tosh J, Lunt M, Davies R, Young A, Verstappen SM. Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts. *Semin Arthritis Rheum*. 44:131-144, 2014

36. Norton S, Sacker A, Dixey J, Done J, Williams P, Young A. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. *Rheumatology (Oxford, England)*. 52:2016-2024, 2013

37. Norton S, Sacker A, Young A, Done J. Distinct psychological distress trajectories in rheumatoid arthritis: findings from an inception cohort. *Journal of psychosomatic research*. 71:290-295, 2011

38. Odegard S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. *Annals of the rheumatic diseases*. 66:1195-1201, 2007

39. Pollard LC, Ibrahim F, Choy EH, Scott DL. Pain thresholds in rheumatoid arthritis: the effect of tender point counts and disease duration. *The Journal of rheumatology*. 39:28-31, 2012

40. Pollard LC, Kingsley GH, Choy EH, Scott DL. Fibromyalgic rheumatoid arthritis and disease assessment. *Rheumatology (Oxford)*. 49:924-928, 2010

41. Prothero L, Barley E, Galloway J, Georgopoulou S, Sturt J. The evidence base for psychological interventions for rheumatoid arthritis: A systematic review of reviews. *Int J Nurs Stud*. 82:20-29, 2018

42. Shi Y, Weingarten TN, Mantilla CB, Hooten WM, Warner DO. Smoking and pain: pathophysiology and clinical implications. *Anesthesiology*. 113:977-992, 2010

43. Shiff NJ, Tupper S, Oen K, Guzman J, Lim H, Lee CH, Bryce R, Huber AM, Boire G, Dancey P, Feldman B, Laxer R, Miettunen P, Schmeling H, Watanabe Duffy K, Levy DM, Turvey S, Bolaria R, Bruns A, Cabral DA, Campillo S, Chedeville G, Feldman DE, Haddad E, Houghton K, Johnson N, Jurencak R, Lang B, Larche M, Morishita K, Ramsey S, Roth J, Schneider R, Scuccimarri R, Spiegel L, Stringer E, Tse SM, Yeung R, Duffy CM, Tucker LB. Trajectories of pain severity in juvenile
idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. *Pain.* 2017

44. Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The association between smoking and low back pain: a meta-analysis. *The American Journal of Medicine.* 123:87 e87-35, 2010

45. Siemons L, Ten Klooster PM, Vonkeman HE, Glas CA, Van de Laar M. Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy. *Arthritis Care Res (Hoboken).* 66:625-630, 2014

46. Silman A, Symmons D, Scott DG, Griffiths I. British Society for Rheumatology Biologics Register. *Ann Rheum Dis.* 62 Suppl 2:i28-29, 2003

47. Ton E, Bakker MF, Verstappen SM, Ter Borg EJ, van Albada-Kuijpers IA, Schenk Y, van der Veen MJ, Bijlsma J, Jacobs JW. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. *The Journal of Rheumatology.* 39:22-27, 2012

48. Van Riel PL: Disease activity score in Rheumatoid arthritis. Available at: http://www.das-score.nl/das28/en/ Accessed 9/10/18, 2018

49. Verhoeven F, Tordi N, Prati C, Demougeot C, Mougin F, Wendling D. Physical activity in patients with rheumatoid arthritis. *Joint Bone Spine.* 83:265-270, 2016

50. Ware JE, Snow KK, Kosinski M: SF-36 health survey: Manual and interpretation guide. 2nd edition, QualityMetric Inc, Lincoln, RI, USA, 2000.

51. Wolfe F, Hauser W, Hassett AI, Katz RS, Walitt BT. The development of fibromyalgia—I: examination of rates and predictors in patients with rheumatoid arthritis (RA). *Pain.* 152:291-299, 2011
Table 1: Baseline demographics and clinical data of participants

Table 1: Sample sizes, means (standard deviations) and percentages are shown for baseline demographics. Complete cases; the subgroup of Data Set for whom SF36-Bodily Pain data are available for all time points. BMI= body mass index; DAS28= Disease Activity Score in 28 joints; HAQ= health assessment questionnaire for disability; CRP= C-reactive protein.

Table 2: Summary of the model selection process

Table 2: Indices and statistics for GMMs using complete cases are shown for models with different numbers of trajectories. ERAN= Early RA Network; BSRBR= British Society for Rheumatology Biologics Register; AIC= Akaike’s information criterion; BIC= Bayesian information criterion; ssBIC= sample size-adjusted BIC; LRT= Lo-Mendell-Rubin likelihood ratio test p value; BLRT= Bootstrapped likelihood ratio test P value. The selected model for each cohort study is shown in bold.

Table 3: Comparison of baseline variables between trajectories

Table 3: Mean (standard deviation) or percentages are shown for each latent trajectory at baseline. P values for heterogeneity between trajectories are shown. In the ERAN data set, significance in pairwise comparisons between Persistent Pain and Resolving Pain trajectories are indicated (* p<0.05 with Bonferonni correction). Higher scores in the SF36 subscales reflect better quality of life. BMI= body mass index; DAS28= Disease Activity Score in 28 joints; VAS-GH= visual analogue scale; TJC= tender joint count; SJC= swollen joint count; HAQ= health assessment questionnaire for disability; ESR= erythrocyte sedimentation rate; CRP= C-reactive protein; Seropositive= positive for Rheumatoid factor or citrullinated proteins.

Table 4: Multinomial logistic regression for Persistent Pain trajectory in each cohort

Table 4: In ERAN the adjusted odds ratios (aOR) for Persistent Pain are displayed, compared to each of the other trajectories. Persistent Pain was used as the reference category, and the aOR and CI’s were then inverted. Multinomial logistic regression was performed; and each aOR indicates the change in risk per unit increase (per year of age, unit of BMI, year of duration, unit of DAS28, unit of HAQ, per point of SF36 subscale). Higher scores in the SF36 subscales reflect better quality of life. Categorical variables aORs showed risks for comorbidities (Yes) and current smoker or ex-smoker compared to never smoked. Statistically significant findings are presented in bold.
Figure 1: Changes over time in reported bodily pain in RA cohorts

Figure 1.
A: Mean SF36-Bodily Pain normed values at each time point are given for (A) each cohort and at each time point from the trajectories yielded by the GMM analysis (B, C, D). B. ERAN cohort. “Low Pain” (23%), “Persistent Pain” (59%) and “Resolving Pain” (19%). C. BSRBR-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%). D. BSRBR-Non-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%). A normed SF36 Bodily Pain score of 50 represents the UK population mean. Higher scores in the SF36 subscales reflect better quality of life.

Figure 2: Trajectories of bodily pain in people with RA with low inflammation measures after 3 years of follow up

Figure 2
Mean values of SF36-Bodily Pain for each trajectory in our sensitivity analysis of people in the BSRBR Biologics cohort who showed a 0/28 swollen joint count and ESR reading of ≤22 (men) or ≤29 (women) at the 3 year study visit (n=1199, with n=570 providing complete pain data). The average pain score for the UK general population is shown as 50. Numbers were not sufficient for analysis in the ERAN cohort (n=180, with n=64 providing complete pain data). Follow up data for these variables were unavailable for BSRBR-Non-Biologics cohort. A normed SF36 Bodily Pain score of 50 represents the UK population mean. Higher scores in the SF36 subscales reflect better quality of life.
Figure 1: Changes over time in reported bodily pain in RA cohorts.
A: Mean SF36-Bodily Pain normed values at each time point are given for (A) each cohort and at each time point from the trajectories yielded by the GMM analysis (B, C, D). 

B. ERAN cohort. “Low Pain” (23%), “Persistent Pain” (59%) and “Resolving Pain” (19%). 
C. BSRBR-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%). 
D. BSRBR-Non-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%). A normed SF36 Bodily Pain score of 50 represents the UK population mean. Higher scores in the SF36 subscales reflect better quality of life.
Figure 2

SF36-Bodily Pain (normed)

- Resolving Pain (n=422)
- Persistent Pain (n=777)

Time

BL 6m 1yr 18m 2yr 30m 3yr
Mean values of SF36-Bodily Pain for each trajectory in our sensitivity analysis of people in the BSRBR Biologics cohort who showed a 0/28 swollen joint count and ESR reading of ≤22 (men) or ≤29 (women) at the 3 year study visit (n=1199, with n=570 providing complete pain data). The average pain score for the UK general population is shown as 50. Numbers were not sufficient for analysis in the ERAN cohort (n=1800, with n=64 providing complete pain data). Follow up data for these variables were unavailable for BSRBR-Non-Biologics cohort. A normed SF36 Bodily Pain score of 50 represents the UK population mean. Higher scores in the SF36 subscales reflect better quality of life.

Table 1: Baseline demographics and clinical data of participants

|                     | ERAN All cases | ERAN Complete cases | BSRBR-Biologics All cases | BSRBR-Biologics Complete cases | BSRBR-Non-Biologics All cases | BSRBR-Non-Biologics Complete Cases |
|---------------------|----------------|---------------------|---------------------------|-------------------------------|-------------------------------|-----------------------------------|
| Sample size         | 683            | 264                 | 7090                      | 3138                          | 1720                          | 605                               |
| Age                 | 57 (13)        | 56 (14)             | 57 (11)                   | 57 (11)                       | 61 (12)                       | 62 (12)                           |
| Female %            | 66%            | 71%                 | 77%                       | 77%                           | 75%                           | 75%                               |
| BMI                 | 28 (5)         | 28 (5)              | 27 (7)                    | 27 (6)                        | 27 (6)                        | 26 (6)                            |
| Smoker %            | 35%            | 30%                 | 19%                       | 17%                           | 19%                           | 16%                               |
| Duration (years)    | 0.8 (1.3)      | 0.8 (1.4)           | 13 (10)                   | 13 (10)                       | 10 (11)                       | 11 (11)                           |
Table 1: Sample sizes, means (standard deviations) and percentages are shown for baseline demographics. Complete cases; the subgroup of Data Set for whom SF36-Bodily Pain data are available for all time points. BMI= body mass index; DAS28= Disease Activity Score in 28 joints; HAQ= health assessment questionnaire for disability; CRP= C-reactive protein.

|             | 1.1 (0.8) | 1.0 (0.7) | 2.0 (0.6) | 2.0 (0.6) | 1.4 (0.8) | 1.3 (0.8) |
|-------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Disability (HAQ) |           |           |           |           |           |           |
| DAS28       | 4.6 (1.6) | 4.7 (1.5) | 6.6 (1.0) | 6.6 (1.0) | 5.0 (1.3) | 4.8 (1.3) |
| CRP         | 23 (32)   | 24 (31)   | 47 (44)   | 48 (44)   | 29 (31)   | 29 (34)   |
| Seropositive % | 63%       | 61%       | 65%       | 65%       | 58%       | 60%       |
Table 2: Summary of the model selection process

| Number of latent trajectories in GMM | 1 trajectory | 2 trajectories | 3 trajectories | 4 trajectories |
|-------------------------------------|--------------|----------------|----------------|---------------|
| **ERAN**                            |              |                |                |               |
| AIC                                 | 7723         | 7687           | **7682**       | 7685          |
| BIC                                 | 7748         | 7723           | **7729**       | 7742          |
| ssBIC                               | 7726         | 7691           | **7688**       | 7692          |
| Entropy                             | 0.709        | 0.665          | 0.63           |               |
| LMR-LRT                             | <0.001       | **0.030**      | 0.636          |               |
| BLRT                                | <0.001       | **0.013**      | 0.654          |               |
| Largest trajectory (%)              | 264 (100%)   | 147 (56%)      | **155 (59%)**  | 106 (40%)     |
| Second largest trajectory (%)       | 117 (44%)    | **60 (23%)**   | 71 (27%)       |               |
| Third largest trajectory (%)        |               |                | 49 (19%)       | 52 (20%)      |
| Fourth largest trajectory (%)       |               |                | 35 (13%)       |               |
| **BSRBR-Biologics**                 |              |                |                |               |
| AIC                                 | 152407       | **152299**     | 152237         | Not done      |
| BIC                                 | 152480       | **152390**     | 152346         |               |
| ssBIC                               | 152442       | **152342**     | 152289         |               |
| Entropy                             | 0.595        | 0.714          |               |               |
| LMR-LRT                             | **0.0491**   | 0.0002         |               |               |
| BLRT                                | <0.0001      | <0.0001        |               |               |
| Largest trajectory (%)              | 3138 (100%)  | **2483 (79%)** | 2430 (77%)     |               |
| Second largest trajectory (%)       | 655 (21%)    | 654 (21%)      |               |               |
Table 2: Indices and statistics for GMMs using complete cases are shown for models with different numbers of trajectories. ERAN=Early RA Network; BSRBR=British Society for Rheumatology Biologics Register; AIC= Akaike’s information criterion; BIC= Bayesian information criterion; ssBIC= sample size-adjusted BIC; LRT= Lo-Mendell-Rubin likelihood ratio test p value; BLRT= Bootstrapped likelihood ratio test P value. The selected model for each cohort study is shown in **bold**.
Table 3: Comparison of baseline variables between trajectories

|                | ERAN             | BSRBR-Biologics | BSRBR-Non-Biologics |
|----------------|------------------|-----------------|---------------------|
|                | Low pain | Persistent pain | Resolving pain | Heterogeneity p value | Resolving pain | Persistent pain | Heterogeneity p value | Resolving pain | Persistent pain | Heterogeneity p value |
| Age            | 55 (15) | 57 (13) | 55 (16) | 0.451 | 54 (12) | 58 (14) | <0.001 | 59 (12) | 62 (11) | <0.001 |
| Female         | 70%     | 74%    | 63%    | 0.329 | 76%     | 77%    | 0.659 | 73%     | 75%    | 0.382 |
| BMI            | 25.8 (3.7) | 28.7 (5.7) | 26.6 (4.5) | <0.001 | 25.7 (5.6) | 27.1 (6.8) | <0.001 | 25.9 (4.9) | 27.3 (5.8) | <0.001 |
| Current smoker | 30%     | 33%    | 29%    | 0.819 | 15%     | 20%    | <0.001 | 16%     | 20%    | <0.001 |
| Duration       | 10 (17) | 9 (11) | 11 (14) | 0.554 | 12 (9)   | 14 (10) | <0.001 | 7 (9)   | 11 (11) | <0.001 |
| Seropositive   | 55%     | 62%    | 68%    | 0.459 | 63%     | 65%    | 0.134 | 57%     | 58%    | 0.678 |
| DAS28          | 3.4 (1.2) | 5.0 (1.4) | 5.0 (1.4) | <0.001 | 6.4 (1.0) | 6.6 (1.0) | <0.001 | 4.5 (1.3) | 5.1 (1.3) | <0.001 |
| VAS-GH         | 21 (16) | 51 (23) | 46 (25) | <0.001 | 70 (20)  | 73 (19) | 0.442 | 42 (25)  | 55 (23) | <0.001 |
| TJC            | 3 (4)   | 9 (7)   | 7 (7)  | <0.001 | 14 (7)   | 16 (7)  | <0.001 | 6 (6)    | 8 (7)  | <0.001 |
| SJC            | 4 (5)   | 7 (6)   | 7 (6)  | 0.002  | 11 (6)   | 11 (6)  | 0.214 | 5 (5)    | 6 (5)  | 0.431 |
| ESR            | 26 (22) | 33 (26) | 43 (32) | 0.017  | 45 (28)  | 47 (29) | 0.030 | 31 (24)  | 34 (23) | 0.094 |
|                | Persistent Pain | Resolving Pain | Persistent Pain | Resolving Pain | Persistent Pain | Resolving Pain | Persistent Pain | Resolving Pain |
|----------------|-----------------|----------------|-----------------|----------------|-----------------|----------------|-----------------|----------------|
| CRP            | 11 (23)         | 27 (30)        | 31 (39)         | 0.022          | 46 (41)        | 48 (45)        | 0.414           | 26 (32)        |
| DAS28-P        | 0.33 (0.12)     | 0.45 (0.10)    | 0.41 (0.09)     | <0.001         | 0.47 (0.08)    | 0.48 (0.07)    | 0.011           | 0.40 (0.11)    |
| Tender-Swollen Difference | -0.60 (4.40) | 2.74 (6.41) | 0.11 (5.77) | <0.001         | 3.22 (7.06)    | 4.45 (7.18)    | <0.001         | 0.75 (5.02)    |
| Comorbidities  | 48%             | 70%            | 57%             | <0.001         | 48%            | 64%            | <0.001         | 50%            |
| Disability (HAQ) | 0.38 (0.41)  | 1.31 (0.72)*   | 1.03 (0.62)*    | <0.001         | 1.7 (0.6)      | 2.1 (0.5)      | <0.001         | 0.8 (0.6)      |
| SF-36 (normed) | Bodily Pain     | 48 (6)         | 30 (9)          | 30 (8)         | 0.001          | 40 (9)         | 30 (7)          | 0.001          |
|                | Physical function | 44 (9)        | 25 (14)         | 30 (12)        | <0.001         | 20 (12)        | 14 (10)         | <0.001         |
|                | Vitality        | 54 (8)         | 39 (10)         | 43 (10)        | <0.001         | 35 (10)        | 32 (10)         | <0.001         |
|                | Mental health   | 55 (8)         | 45 (11)         | 49 (9)         | <0.001         | 44 (11)        | 40 (11)         | <0.001         |

Table 3: Mean (standard deviation) or percentages are shown for each latent trajectory at baseline. P values for heterogeneity between trajectories are shown. In the ERAN data set, significance in pairwise comparisons between Persistent Pain and Resolving Pain trajectories are indicated (* p<0.05 with Bonferroni correction). Higher scores in the SF36 subscales reflect better quality of life. BMI= body mass index; DAS28= Disease Activity Score in 28 joints; VAS-GH=visual analogue scale; TJC= tender joint count; SJC= swollen joint count; HAQ= health assessment questionnaire for disability; ESR= erythrocyte sedimentation rate; CRP= C-reactive protein; Seropositive= positive for Rheumatoid factor or citrullinated proteins.
Table 4: Multinomial logistic regression for Persistent Pain trajectory in each cohort

|                | ERAN Persistent Pain (vs Low Pain) | ERAN Persistent Pain (vs Resolving Pain) | BSRBR-Biologics | BSRBR-Non-Biologics |
|----------------|-----------------------------------|-----------------------------------------|-----------------|---------------------|
| aOR (95% CI)   | p                                 | aOR (95% CI)                            | p               | aOR (95% CI)        | p |
| Age            | 1.01 (0.99 - 1.04)                 | 0.340                                   | 0.99 (0.98 - 1.01) | 0.550               | 1.02 (1.01 - 1.03) | <0.001 |
| BMI            | 1.02 (0.95 - 1.10)                 | 0.553                                   | 1.00 (0.96 - 1.05) | 0.947               | 1.03 (1.02 - 1.05) | <0.001 |
| Duration       | 1.02 (0.97 - 1.06)                 | 0.457                                   | 0.99 (0.98 - 1.00) | 0.123               | 1.02 (1.01 - 1.02) | <0.001 |
| Current smoker | 1.16 (0.52 - 2.56)                 | 0.717                                   | 1.83 (1.05 - 3.18) | 0.032               | 1.72 (1.41 - 2.11) | <0.001 |
| Ex-smoker      | 4.65 (1.73 - 12.50)                | 0.002                                   | 1.52 (0.86 - 2.67) | 0.146               | 1.17 (1.00 - 1.37) | 0.045 |
| DAS28          | 0.91 (0.67 - 1.24)                 | 0.542                                   | 0.54 (0.69 - 1.02) | 0.073               | 0.91 (0.84 - 0.99) | 0.019 |
| Disability (HAQ) | 5.43 (2.44 - 12.05)             | <0.001                                   | 2.31 (1.51 - 3.56) | <0.001               | 2.36 (2.05 - 2.73) | <0.001 |
| CoMorbidity    | 1.18 (0.57 - 2.48)                 | 0.655                                   | 1.28 (0.78 - 2.09) | 0.332               | 1.39 (1.20 - 1.60) | <0.001 |
| Bodily Pain    | 0.76 (0.70 - 0.81)                 | <0.001                                   | 1.02 (0.99 - 1.06) | 0.224               | 0.98 (0.97 - 0.99) | <0.001 |
| Vitality       | 0.99 (0.95 - 1.03)                 | 0.579                                   | 0.97 (0.94 - 1.00) | 0.028               | 1.00 (0.99 - 1.01) | 0.704 |
| Mental Health  | 1.02 (0.98 - 1.07)                 | 0.318                                   | 0.99 (0.96 - 1.02) | 0.425               | 0.98 (0.97 - 0.99) | <0.001 |

Table 4: In ERAN the adjusted odds ratios (aOR) for Persistent Pain are displayed, compared to both of the other trajectories. Persistent Pain was used as the reference category, and the aOR and CI’s were then inverted. Multinomial logistic regression was performed; and each aOR indicates the change in risk per unit increase (per year of
age, unit of BMI, year of duration, unit of DAS28, unit of HAQ, per point of SF36 subscale). Higher scores in the SF36 subscales reflect better quality of life. Categorical variables aOR’s showed risk directly compared to a reference category (No comorbidities and Never smoked). Statistically significant findings are presented in bold.